Jacob J. Adashek

South Texas Accelerated Research Therapeutics

Also affiliated with Center for Cancer Research, Johns Hopkins Hospital, Sidney Kimmel Comprehensive Cancer Center

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

3in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 3 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Data from Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors

(2023)10.1158/1535-7163.c.6543276.v1

Top 100%

0DataRank

Top 100%0 citations

Arjun K. Menta, Neha K. Reddy, Aakash Desai, Jason Roszik, Vivek Subbiah +1 more

Papers

Driven by 24 papers — median percentile 0. Top paper: “Hallmarks of RET and Co-occuring Genomic Alterations inRET-aberrant Cancers”.

Hallmarks of RET and Co-occuring Genomic Alterations inRET-aberrant Cancers

Molecular Cancer Therapeutics(2021)10.1158/1535-7163.mct-21-0329

N/A

1.5DataRank · unranked

45 citations

Aakash Desai, Alexander Andreev-Drakhlin, Jason Roszik, Gilbert J. Cote, Vivek Subbiah +1 more

Targeting G1/S phase cell-cycle genomic alterations and accompanying co-alterations with individualized CDK4/6 inhibitor–based regimens

JCI Insight(2021)10.1172/jci.insight.142547

N/A

1.1DataRank · unranked

31 citations

Ryosuke Okamura, Jacob J. Adashek, Noor Khalid, Suzanna Lee, Van Thomas Nguyen +3 more

Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy

Nature Communications(2020)10.1038/s41467-020-18613-3

N/A

0.859DataRank · unranked

305 citations

Ki Hwan Kim, Hyo Jeong Lim, Amélie Boichard, Mina Nikanjam, Elizabeth Weihe +17 more

Considering molecular alterations as pan-cancer tissue-agnostic targets

Nature Cancer(2023)10.1038/s43018-023-00676-y

N/A

0.693DataRank · unranked

11 citations

Shumei Kato, Jason K. Sicklick, Scott M. Lippman, Razelle Kurzrock, Jacob J. Adashek

Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-3761

N/A

0.561DataRank · unranked

41 citations

Jacob J. Adashek, Justin Shaya, Ryosuke Okamura, Rebecca E. Jimenez, Suzanna Lee +3 more

Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors

Molecular Cancer Therapeutics(2022)10.1158/1535-7163.mct-21-0950

N/A

0.557DataRank · unranked

40 citations

Arjun K. Menta, Neha K. Reddy, Aakash Desai, Jason Roszik, Vivek Subbiah +1 more

Viewing the immune checkpoint VISTA: landscape and outcomes across cancers

ESMO Open(2024)10.1016/j.esmoop.2024.102942

N/A

0.524DataRank · unranked

32 citations

Razelle Kurzrock, Hirotaka Miyashita, Jacob J. Adashek, Suzanna Lee, Mina Nikanjam +10 more

LAG‐3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeutics

Cancer Medicine(2023)10.1002/cam4.6000

N/A

0.524DataRank · unranked

32 citations

Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Pradip De, Suzanna Lee +7 more

Pan‐cancer analysis of TIM‐3 transcriptomic expression reveals high levels in pancreatic cancer and interpatient heterogeneity

Cancer Medicine(2023)10.1002/cam4.6844

N/A

0.514DataRank · unranked

13 citations

Razelle Kurzrock, Daisuke Nishizaki, Hirotaka Miyashita, Jacob J. Adashek, Suzanna Lee +7 more

If it’s a target, it’s a pan-cancer target: Tissue is not the issue

Cancer Treatment Reviews(2024)10.1016/j.ctrv.2024.102721

N/A

0.510DataRank · unranked

29 citations

Shumei Kato, Jason K. Sicklick, Scott M. Lippman, Razelle Kurzrock, Jacob J. Adashek

Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional response

Journal of Hematology & Oncology(2022)10.1186/s13045-022-01344-x

N/A

0.385DataRank · unranked

12 citations

Shumei Kato, Pradip De, Jacob J. Adashek, Jason K. Sicklick, Vivek Subbiah +2 more

Multi‐omic analysis in carcinoma of unknown primary ( CUP ): therapeutic impact of knowing the unknown

Molecular Oncology(2022)10.1002/1878-0261.13293

N/A

0.385DataRank · unranked

12 citations

Sophia Gumas, Jacob J. Adashek, Ryosuke Okamura, Suzanna Lee, Jason K. Sicklick +2 more

Targeting G1-S phase cell-cycle alterations with CDK4/6 inhibitor-based genomically matched personalized therapy approach.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.3623

N/A

0.104DataRank · unranked

1 citations

Shumei Kato, Ryosuke Okamura, Noor Khalid, Suzanna Lee, Van Thomas Nguyen +3 more

The abscopal effect in patients with cancer receiving immunotherapy

Med(2023)10.1016/j.medj.2023.02.003

N/A

0DataRank · unranked

68 citations

Jacob J. Adashek, Steven H. Lin, Vivek Subbiah, Blessie Elizabeth Nelson

Balancing clinical evidence in the context of a pandemic

Nature Biotechnology(2021)10.1038/s41587-021-00834-6

N/A

0DataRank · unranked

11 citations

Razelle Kurzrock, Jacob J. Adashek

Data from Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics

(2023)10.1158/1078-0432.c.6529977

N/A

0DataRank · unranked

0 citations

Jacob J. Adashek, Justin Shaya, Ryosuke Okamura, Rebecca E. Jimenez, Suzanna Lee +3 more

Data from Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors

(2023)10.1158/1535-7163.c.6543276.v1

Top 100%

0DataRank

Top 100%0 citations

Arjun K. Menta, Neha K. Reddy, Aakash Desai, Jason Roszik, Vivek Subbiah +1 more

Data from Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors

(2023)10.1158/1535-7163.c.6543276

Top 100%

0DataRank

Top 100%0 citations

Arjun K. Menta, Neha K. Reddy, Aakash Desai, Jason Roszik, Vivek Subbiah +1 more

Signed in Blood: Circulating Tumor DNA in Cancer Diagnosis, Treatment and Screening

Cancers(2021)10.3390/cancers13143600

N/A

0DataRank · unranked

93 citations

Filip Jankú, Razelle Kurzrock, Jacob J. Adashek

Reverse repurposing: Potential utility of cancer drugs in nonmalignant illnesses

Med(2024)10.1016/j.medj.2024.04.008

N/A

0DataRank · unranked

7 citations

Kaitlyn Wells, Shumei Kato, Jacob J. Adashek, Shanna Block, Razelle Kurzrock +1 more

Toll-like receptor 3: a double-edged sword

Biomarker Research(2025)10.1186/s40364-025-00739-5

N/A

0DataRank · unranked

33 citations

Daisuke Nishizaki, Jacob J. Adashek, Shumei Kato, Razelle Kurzrock, Marvin L Hsieh

Tumour-agnostic kinase inhibitors

Nature Reviews Drug Discovery(2025)10.1038/s41573-025-01147-y

N/A

0DataRank · unranked

14 citations

Mina Nikanjam, Razelle Kurzrock, Jacob J. Adashek

Predicting the Abscopal Effect: Associated Tumor Histologic Subtypes and Biomarkers

Molecular Cancer Therapeutics(2023)10.1158/1535-7163.mct-22-0516

N/A

0DataRank · unranked

20 citations

Jacob J. Adashek, Aakash Akshay Sheth, Vivek Subbiah, Blessie Elizabeth Nelson

Recent advancements in the treatment of metastatic clear cell renal cell carcinoma: A review of the evidence using second-generation p-values

Cancer Treatment and Research Communications(2020)10.1016/j.ctarc.2020.100166

N/A

0DataRank · unranked

32 citations

Giannicola Genovese, Nizar M. Tannir, Pavlos Msaouel, Jacob J. Adashek

Jacob J. Adashek

Indexed papers

Top data-sharing exemplar

Papers